August 2014 Issue of The Ophthalmologist

Population-level disease prophylaxis with statins has improved the lives of millions. But there has been some protest about this mass medication. Is the next battle not with disease, but with the press?

Is the potential dystopia that is myopia a consequence of too much study?

Might you soon take a skin cell from a patient with retinitis pigmentosa, roll it back to a pluripotent state, culture it to become retinal cells and trial gene therapy on it in vitro?

Oral replacement therapy of the retinoid intermediate that fails to form in some types of Leber congenital amaurosis shows significant promise in an early-phase clinical trial

SIRT1 appears to be an anti-aging protein that protects against weight gain, diabetes, inflammation, and even optic neuritis… in mouse models. Is SIRT1 the key to eternal youth, or simply snake oil?

Identifying corneal limbal stem cells for transplantation has been a major challenge. But now a highly specific marker of these cells has been found: ABCB5

A student lost sight in one eye after failing to remove her disposable contact lenses for six months. So how did tabloid journalists turn it into such a popular news story?

We look to the oldest in society to understand the contribution of poor nutrition to ophthalmic disease

Limbal relaxing incisions were a large part of my approach to treating astigmatism in patients undergoing cataract surgery. No longer…

Popular culture has always viewed eyes as being things of beauty. But there’s more to the eye than the color of your irides.

Sitting Down With Jim Mazzo, Operating Partner at Versant Ventures.